Trial Profile
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2021
Price :
$35
*
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Genentech
- 02 Nov 2016 Status changed from active, no longer recruiting to completed.
- 14 Dec 2014 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
- 04 Nov 2014 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov record.